Pathological correlates of extrapyramidal signs in Alzheimer's disease

Annals of Neurology

Volumn 41, Issue 3, 1997, Pages 368-374

  Liu, Yan ^a,c   Stern, Yaakov ^a   Chun, Michael R ^b   Jacobs, Diane M ^a   Yau, Patricia ^a   Goldman, James E ^a  

^a Columbia University ^*  (United States)

^b Providence Everett Medical Center   (United States)

^c Department of Pathology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BASAL GANGLION; BRAIN DEGENERATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HUMAN TISSUE; LEWY BODY; MALE; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BASAL GANGLIA; CASE-CONTROL STUDIES; CEREBRAL CORTEX; EXTRAPYRAMIDAL TRACTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROFIBRILLARY TANGLES; NEURONS; SUBSTANTIA NIGRA;

EID: 0031051858     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410410312     Document Type: Article

References (23)

1. Stern Y, Albert M, Brandt J, et al. Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease; prospective analyses from the predictors study. Neurology 1994;44:2300-2307
2. Motreil JC, Drazner M, Fulling K, et al. Clinical and pathological aspects of parkinsonism in Alzheimer's disease. Arch Neurol 1989;46:651-657
3. Rinne JO, Rummukainen J, Paljärvi L, Rinne UK. Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra. Ann Neurol 1989;26:47-50
4. Mölsä PK, Säko E, Paljärvi L, et al. Alzheimer's disease: neuropathological correlates of cognitive and motor disorders. Acta Neurol Scand 1987;75:376-384
5. Ditter SM, Mirra SS. Neuropathologic and clinical features of Parkinson's disease in Alzheimer's disease patients. Neurology 1987;37:754-760
6. Leverenz J, Sumi SM. Parkinson's disease in patients with Alzheimer's disease. Arch Neurol 1986;43:662-664
7. Maslish E, Mallory M, De Teresa R, et al. Differing patterns of aberrant neuronal sprouting in Alzheimer's disease with and without Lewy bodies. Brain Res 1993;617:258-266
8. Reinikainen KJ, Paljärvi L, Halonen T, et al. Dopaminergic system and monoamine oxidase-B activity in Alzheimer's disease. Neurobiol Aging 1988;9:245-252
9. Uchihara T, Kondo H, Kosaka K, Tsukagoshi H. Selective loss of nigral neurons in Alzheimer's disease: a morphometric study. Acta Neuropathol (Berl) 1992;83:271-276
10. Gibb WRG, Mountjoy CQ, Mann DMA, Lees AJ. The substantia nigra and ventral tegmental area in Alzheimer's disease and Down's syndrome. J Neurol Neurosurg Psychiatry 1989; 52:193-200
11. Murray AM, Weihmueller FB, Marshall JF, et al Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism. Ann Neurol 1995;37:300-312
12. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944
13. Stern MB. The clinical characteristics of Parkinson's disease and parkinsonian syndromes: diagnosis and assessment. In: Stern MB, Hurtig HI, eds. The comprehensive management of Parkinson's disease. New York: PMA, 1988:3-50
14. Richards M, Marder K, Bell K, et al. Interrater reliability of extrapyramidal signs in a group assessed for dementia. Arch Neurol 1991;48:1147-1149
15. Hulette C, Mirra S, Wilkinson W, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part IX. A prospective cliniconeuropathologic study of Parkinson's features in Alzheimer's disease. Neurology 1995;45:1991-1995
16. Yen SH, Crowe A, Dickson DW. Monoclonal antibodies to Alzheimer neurofibrillary tangles. 1. Identification of polypeptides. Am J Pathol 1985;120:282-291
17. Braak E, Braak H, Mandelkow EM. A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol (Berl) 1994;87:554-567
18. Gallyas F. Silver staining of Alzheimer's neurofibrillary changes by means of physical development. Acta Morphol Acad Sci Hung 1971;19:1-8
19. Lennox G, Lowe J, Morrell R, et al. Antiubiquitin immunocytochemistry is more sensitive than conventional techniques in the detection of diffuse Lewy body disease. J Neurol Neurosurg Psychiatry 1989;52:67-71
20. Abercrombie M. Estimation of nuclear populations from microtome sections. Anat Rec 1946;94:239-247
21. Pakkenberg B, Moller A, Gundersen HJG, et al. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry 1991;54: 30-33
22. Moller A. Mean volume of pigmented neurons in the substantia nigra in Parkinson's disease. Acta Neurol Scand Suppl 1992; 137:37-39
23. Chui HC, Lyness SA, Sobel E, Schneider LS. Extrapyramidal signs and psychiatric symptoms predict raster cognitive decline in Alzheimer's disease. Arch Neurol 1994;51:676-681